



Vectura: Specialists in Inhalation

Vectura builds on its track record with a new focus as an inhalation CDMO, helping companies bring their medicines to market



Vectura is the inhaled product development specialist, combining formulation and device technology with product development expertise to help customers succeed in bringing their inhaled medicines to market.

The company's entire focus is inhalation. Whether customers are working on small or large molecules, for a small biotech or large pharmaceutical company, Vectura can offer expertise at every stage of the development pathway.

With more than 20 years' experience in inhaled product development, its formulation and device technology has contributed to the success of 11 inhaled medicines, launched by partners and licensees. Since launch, these products have generated \$10 billion in sales and, in 2018, were used by 9 million patients worldwide.


The company's track record of successfully developing products for partners to bring to market is extremely important now that Vectura has shifted its strategy to become a

specialist contract development and manufacturing organisation (CDMO) in the inhalation space.

Vectura's new customers can rest assured that the company has a real pedigree of accomplishment and can be relied upon to help them achieve success with their medicines.

Customers today are looking for partners that can provide differentiated technology, excellent science, consistent outstanding quality, reliable solutions, and excellent customer service in equal measure. Vectura is well positioned to meet these market needs in a segment that has strong underlying growth. Vectura's services include:

- Formulation and product development – developing advanced formulations for novel or generic products, small molecules or biologics
- Pharmaceutical analysis – with a large, experienced analytical team able to undertake the complete spectrum of test methodologies required to support the development



of dry powder inhalers (DPI), pressurised metered dosed inhalers (pMDI), and nebulised products

- Device development – Vectura are one of the few companies globally that have developed DPI, pMDI, and nebulisers to deliver a broad range of complex inhaled therapies
- Process development, technical transfer & manufacturing – Vectura can support development from feasibility through to transfer to commercial production, as well as manage commercial device supply through its network of suppliers.

Will Downie, who joined Vectura as CEO in November 2019, said: "In my 10 years in the CDMO space, I have never seen better technology and scientific expertise than we have in Vectura. It's an exciting time for the company as we progress and innovate to help more customers bring their medicines to patients."

Contact
 Vectura
www.vectura.com
businessdevelopment@vectura.com